Squarepoint Ops LLC Sells 113,545 Shares of Twist Bioscience Corporation $TWST

Squarepoint Ops LLC cut its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 74.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 39,981 shares of the company’s stock after selling 113,545 shares during the quarter. Squarepoint Ops LLC’s holdings in Twist Bioscience were worth $4,113,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Royal Bank of Canada raised its stake in Twist Bioscience by 11.8% during the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after purchasing an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Twist Bioscience by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after buying an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Twist Bioscience by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after buying an additional 37,577 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Twist Bioscience by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after buying an additional 4,591 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Twist Bioscience in the 2nd quarter worth about $737,000.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Canaccord Genuity Group increased their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Piper Sandler boosted their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Guggenheim restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Robert W. Baird upped their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.45.

Insiders Place Their Bets

In related news, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the sale, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 291 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the transaction, the senior vice president directly owned 120,414 shares in the company, valued at $10,514,550.48. This trade represents a 0.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 193,109 shares of company stock worth $24,049,024. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Price Performance

TWST stock opened at $127.22 on Friday. The stock has a market cap of $7.98 billion, a PE ratio of -57.31 and a beta of 2.22. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $155.44. The company has a 50-day moving average price of $113.51 and a 200 day moving average price of $79.33. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. Equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.